AstraZeneca Resumes Covid Vaccine Trials After Independent Committee Approves Of Safety

AstraZeneca plc AZN can heave a sigh of relief following resumption of its coronavirus vaccine study that was voluntarily paused by the company.

What Happened: The U.K. pharma giant said U.K. regulatory agency, the Medicines Health Regulatory Authority (MHRA) has given its concurrence to resume the late-stage study of AZD1222 — the vaccine candidate it is jointly developing with the Oxford University against SARS-CoV-2.

Following a standard review process, AstraZeneca paused all global trials on Sept. 6 after an unidentified illness was reported in one of the trial participants. The company later clarified that the person was a woman in the U.K., who experienced symptoms associated with transverse myelitis, a spinal inflammatory disorder.

The pause was to allow review of safety data by independent committees, and international regulators.

The U.K. independent committee has concluded its investigations and recommended to MHRA that the trials in the U.K. are safe to resume.

The company, however, said further medical information cannot be disclosed.

"All trial investigators and participants will be updated with the relevant information and this will be disclosed on global clinical registries, according to the clinical trial and regulatory standards," AstraZeneca said.

Why It's Important: AstraZeneca was hustling to develop a vaccine for the novel coronavirus, and was considered to be among the frontrunners in the race.

The pause prompted analysts and researchers to suggest the company might be ceding the first-to-market advantage in a highly competitive arena.

Apart from AstraZeneca, there are a host of others which have their respective vaccine candidates either in early- or mid-stage trials. The Pfizer Inc. PFE/BioNTech SE - ADR BNTX team and Moderna Inc. MRNA are currently conducting late-stage studies.

The late-Tuesday disclosure of the pause led to a 2% decline in AstraZeneca shares on Wednesday. At the same time, stocks of other coronavirus vaccine makers moved higher in the session.

The trial resumption should help AstraZeneca proceed with the studies, without impacting the timelines.

Related Links:

Pfizer, BioNTech Rally On A Trio Of Catalysts

As Political Pressure Mounts, COVID-19 Vaccine Developers Pledge To Put Safety First

Posted In: AstraZenecaCoronavirusCoronavirus VaccineCovid-19BiotechNewsHealth CareGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.